EUVIMEDEUVIMED entdecken
Übersichtsarbeit

AGEs RAGE Pathways: Alzheimer’s Disease

Shubhrat Maheshwari

Drug Research · 01.06.2023 · 73 (05) · 251-254

DOI: 10.1055/a-2008-7948 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Research, erschienen am 01.06.2023. Verfasst von Shubhrat Maheshwari. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, Rama University, Kanpur, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurofibrillary tangles and plaques containing tau serve as the biological markers for Alzheimer disease (AD) and pathogenesis is widely believed to be driven by the production and deposition of the β-amyloid peptide (Aβ). The β-amyloid peptide (Aβ) that results from the modification of the amyloid precursor protein (APP) by builds up as amyloid deposits in neuronal cells. Thus, a protein misfolding process is involved in the production of amyloid. In a native, aqueous buffer, amyloid fibrils are usually exceedingly stable and nearly insoluble. Although amyloid is essentially a foreign substance made of self-proteins, the immune system has difficulty identifying and eliminating it as such for unknown reasons. While the amyloidal deposit may have a direct role in the disease mechanism in some disease states involving amyloidal deposition, this is not always the case. Current research has shown that PS1 (presenilin 1) and BACE (beta-site APP-cleaving enzyme) have – and -secretase activity that increases β-amyloid peptide (Aβ). Wealth of data has shown that oxidative stress and AD are closely connected that causes the death of neuronal cells by producing reactive oxygen species (ROS). Additionally, it has been demonstrated that advanced glycation end products (AGEs) and β-amyloidal peptide (Aβ) together increase neurotoxicity. The objective of this review is to compile the most recent and intriguing data of AGEs and receptor for advanced glycation end products (RAGE) pathways which are responsible for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansReceptor for Advanced Glycation End ProductsAmyloid beta-Protein PrecursorAmyloid beta-PeptidesGlycation End Products, Advanced

Substanzen

Receptor for Advanced Glycation End ProductsAmyloid beta-Protein PrecursorAmyloid beta-PeptidesGlycation End Products, Advanced

Autor:innen und Institutionen

  • Faculty of Pharmaceutical Sciences, Rama University, Kanpur, Uttar Pradesh, India.

Zitieren

APA

Maheshwari, S. (2023). AGEs RAGE Pathways: Alzheimer’s Disease. Drug Research, 73(05), 251-254. https://doi.org/10.1055/a-2008-7948

Vancouver

Maheshwari S. AGEs RAGE Pathways: Alzheimer’s Disease. Drug Research. 2023;73(05):251-254. doi:10.1055/a-2008-7948

BibTeX
@article{Maheshwari2023,
  author = {Maheshwari, Shubhrat},
  title = {AGEs RAGE Pathways: Alzheimer’s Disease},
  journal = {Drug Research},
  year = {2023},
  volume = {73},
  number = {05},
  pages = {251--254},
  doi = {10.1055/a-2008-7948}
}
Kostenlos starten →